Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 813

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 813
---
137,000 |   |
| Change in fair value                                            |     |            |          — |   |
| Balance as of December 31, 2023                                 |     | $          |    137,000 |   |
| Additions (make-whole provision in convertible notes agreement) |     |            |  2,402,228 |   |
| Change in fair value                                            |     |            |    313,772 |   |
| Reclassification to additional paid-in capital                  |     |            | (2,853,000 | ) |
| Balance as of December 31, 2024                                 |     | $          |          — |   |

Note 6 - Merger with Kintara Therapeutics Under the terms of the Merger, immediately prior to the effective time of the Merger, shares of the Company’s preferred stock were converted into shares of Company common stock and all of the Notes issued by the Company were converted into shares of Company common stock pursuant to the terms therein. At the effective time of the Merger, (i) Kintara issued an aggregate of approximately 40,441,605 shares of its common stock to Company stockholders, based on an exchange ratio of 0.1789 (after giving effect to the Reverse Stock Split) shares of Kintara’s common stock for each share of Company common stock outstanding immediately prior to the Merger, (ii) each then-outstanding Company stock option was assumed and converted into an option to purchase shares of Kintara common stock subject to certain adjustments based on the exchange ratio as set forth in the Merger Agreement, and (iii) each then-outstanding warrant to purchase shares of Company Common Stock was assumed and converted into and exchangeable based on the exchange ratio for a warrant of like tenor entitling the holder to purchase shares of Kintara common stock. F-82

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023 The Merger is accounted for as a reverse recapitalization. Immediately after the merger, there were 42,032,165 shares of the Company’s common stock outstanding. The following table shows the net liabilities assumed in the merger:

|                                                             |     | October 18, 
 2024        |            |   |
|:------------------------------------------------------------|:----|:------------|-----------:|:--|
| Cash and